logo
A genetic test could predict the odds of obesity, allowing for early interventions

A genetic test could predict the odds of obesity, allowing for early interventions

Yahoo21-07-2025
A genetic test may one day predict a child's risk of obesity in adulthood, paving the way for early interventions.
Certain genetic variants can affect how a person's body stores fat or make them more prone to overeating. Genetic variation can also predict how well a person will respond to different weight loss drugs.
In a study published Monday in the journal Nature Medicine, more than 600 researchers from around the world worked together to compile genetic data from more than 5 million people — the largest and most diverse genetic dataset to date. They also used genetic data from 23andMe.
From the dataset, the researchers were able to create what's known as a polygenic risk score, which takes into account which genetic variants a person has that have been linked to a higher BMI in adulthood.
The score, the researchers said, could be used to predict a person's risk of obesity as an adult — before they even turn 5.
'Childhood is the best time to intervene,' said study co-author Ruth Loos, a professor at the University of Copenhagen's Novo Nordisk Foundation Center for Basic Metabolic Research. (Research conducted at the center is not influenced by drugmaker Novo Nordisk, though some of the study authors had ties to pharmaceutical companies that make weight loss drugs.)
The findings come as obesity is rising around the world. Rates of obesity in adults have more than doubled globally since 1990, and adolescent rates have quadrupled, according to the World Health Organization. About 16% of adults worldwide have obesity and the situation is worse in the United States, where more than 40% of adults have obesity, Centers for Disease Control and Prevention statistics show.
Twice as effective
The new test is not the first that predicts a person's risk of obesity, but Loos and her team showed it was about twice as effective as the method doctors currently use to assess their patients. That polygenetic score can account for about 8.5% of a person's risk for having a high BMI as an adult. The new score increased that to about 17.6%, at least in people with European ancestry.
'That's a pretty powerful risk indicator for obesity, but it still leaves open a lot that is unknown,' said Dr. Roy Kim, a pediatric endocrinologist at Cleveland Clinic Children's who was not involved with the research.
Based on this score, more than 80% of a person's risk for obesity can be explained by other factors, such as where they live, what kinds of foods they have access to, and how much they exercise.
The test was not nearly as effective in predicting obesity risk in non-Europeans. It explained about 16% of the risk for having a high BMI in East Asian Americans, but just 2.2% in rural Ugandans.
About 70% of people whose data was included in the study were of predominantly European ancestry. About 14% were Hispanic and typically had a mix of ancestries. About 8% were of predominantly East Asian descent and just under 5% were of predominantly African ancestry. These samples were predominantly from African American people, who largely had mixed ancestry. Just 1.5% were of predominantly South Asian ancestry.
Loos said the new score is a big step forward, but that it's still a prototype. The next step is to collect more — and more diverse — data on people with African ancestry in particular to improve how well the score works for everyone, not just white people.
She said the score could offer one indicator — what high blood pressure is to heart disease, for example — that could help predict a person's risk of developing obesity.
'Obesity is not only about genetics, so genetics alone can never accurately predict obesity,' Loos said. 'For the general obesity that we see all over the world, we need other factors such as lifestyle that need to be part of the predictions.' Genetics play a bigger role in severe obesity, meaning a BMI of more than 40, she added.
Still, identifying a person's genetic risk early on in childhood and intervening early with lifestyle coaching could make a big difference, she said. Research has shown that about 55% of children with obesity go on to have obesity in adolescence, and that about 80% of those individuals will have obesity in adulthood.
'Behavioral things are really important,' Kim said. 'Their environment, their access to healthy food, exercise opportunities, even their knowledge about healthy foods all affect a person's obesity risk.'
How important are genetics, really?
Although studies in identical twins have found that genetics can account for as much as 80% of the reason a person has obesity, lifestyle factors still play a huge role, Kim said.
'Even with the same genetic makeup, people can have different body types,' he said. 'From a very young age in my practice, we educate patients about the importance of eating protein-rich foods, a lot of fruits and vegetables and not too many refined carbs.'
Dr. Juliana Simonetti, co-director of the Comprehensive Weight Management Program at the University of Utah, has been using genetic testing in her adult patients for about five years. She said understanding a person's genes can help doctors better treat weight gain.
'Obesity is not homogeneous. We have different kinds and different presentations,' said Simonetti, who wasn't involved with the new study.
Simonetti uses a person's genes to determine if a patient struggles with satiety, or feeling full.
'They eat but do not feel full,' Simonetti said, adding that this is a disorder caused by genetic mutations affecting certain pathways in the body. People who have these mutations 'tend to have higher weight,' she said.
But such mutations do not tell the whole genetic story of obesity, Simonetti said. The genes that a person inherits from either parent, even if they are not mutations, also determine how a person's body stores weight or uses energy. Both can play a big role in obesity risk.
Genetic testing is also starting to be able to determine how well certain weight loss drugs will work for a person, Simonetti said, but she added this is just the beginning.
'We are talking about three out of 80 mutations that we can treat,' she said. 'We are getting better, and the more data we have, I'm hopeful that we are going to do a better job in being more precise in understanding treatment responses.'
This article was originally published on NBCNews.com
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook

Yahoo

time24 minutes ago

  • Yahoo

Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook

Novo Nordisk's (NVO) downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ability to maintain a market lead in the obesity drug space. The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen told reporters Tuesday that the compounding, or copycat, market in the US is to blame. That is one of two key issues that appear to have taken the company by surprise. First was the shortage of both its GLP-1 drugs after they unexpectedly zoomed to popularity, creating a new weight-loss drug market. Jørgensen said that the prevalence of compounded products, which are now restricted after the FDA declared an end to the shortage, is to blame. "Despite the fact that it is now illegal ... it's still happening. And that's one of the assumptions in the prior guidance, that that would be reduced significantly. And we see, actually, that is actually the same volume as we saw earlier in the year, around a million patients using a compounded product," Jørgensen said. The compounded products include those from Novo's ex-partner, Hims & Hers (HIMS), which continues to sell the products based on a loophole in FDA rules that allows it to sell "personalized" products for patients who might have negative reactions or side effects to branded drugs — such as common GLP-1 side effects like nausea or dizziness. Novo recently ended its direct-to-consumer sales deal with Hims after the telehealth firm declined to stop selling compounded semaglutide vials. The result has been a loss in the company's first-to-market position, with competitor Eli Lilly (LLY) taking a harder stance, most recently lobbying Congress to help enforce the FDA rules and rid the market of compounding. Jørgensen said Tuesday, "Ultimately, compounding will disappear. But it will take some time before it's completely out of the market and we have a fair chance of regaining our fair share (of the market)." Incoming CEO Mike Doustdar, who has served as Novo's executive vice president of international operations, said the decline of the company's stock, and therefore shareholder value, is disappointing. "I don't like it as an employee ... as a CEO-elect, and I certainly don't like it as a shareholder myself. But setbacks don't define companies, our response does," Doustdar said, adding that the guidance cut reinforces his mandate to put the company back onto a growth path. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices

Scientists Witnessed the Birth of a Monster—8.3 Billion Years After It Happened
Scientists Witnessed the Birth of a Monster—8.3 Billion Years After It Happened

Yahoo

time40 minutes ago

  • Yahoo

Scientists Witnessed the Birth of a Monster—8.3 Billion Years After It Happened

Here's what you'll learn when you read this story: Observations from NASA's James Webb Space Telescope and other telescopes have shown what appears to be a supermassive black hole forming right between two merging galaxies. There have been multiple hypotheses surrounding supermassive black hole formation, but these observations support the hypothesis that suggests these behemoths are the result of immense clouds of shocked and compressed gas collapsing in on themselves. Future observations with Webb may finally confirm how supermassive black holes come into being. Supermassive black holes lurk in almost every large galaxy, including our own, but their origins are more elusive. Did they appear after the demise of gargantuan stars in the early universe? Do they form from smaller black holes that merge? Is it possible they emerge from monstrous clouds of star-forming gas that collapse in on themselves? That last hypothesis might be onto something. The pair of galaxies merging into what is now known as the Infinity Galaxy (so named because of its uncanny resemblance to the infinity symbol) is 8.3 billion light-years away, meaning we are seeing events unfold as they did that many billions of years ago. Between them is what astronomers now believe to be a supermassive black hole (SMBH) in its infancy. Whatever the object is, it is accreting tons upon tons of material, and supermassive black holes are known for their voracious appetites. Observations of this galaxy and the thing spawning in the middle might be the first hard evidence of a supermassive black hole being born. Each of the galaxies that collided to form the Infinity Galaxy have their own glowing nuclei containing supermassive black holes, but the one supposedly forming in between is unrelated to either of them—its source is apparently something else. The mystery convinced astronomers Pieter van Dokkum of Yale University and Gabriel Brammer of the University of Copenhagen, who discovered the nascent black hole while analyzing images from the COSMOS-Web survey of NASA's James Webb Space Telescope, that what they were seeing was no ordinary star. Van Dokkum and Brammer backed their findings up by poring over data from observations made by the W.M. Keck Observatory, the Chandra X-Ray Observatory, and more data from the archives of the National Radio Astronomy Observatory's Very Large Array. It was already strange that this black hole was not hiding in the nucleus of a galaxy, never mind that it was at the beginning of its life. Shrouded by clouds of gas between the two galaxies was most likely a supermassive black hole that probably formed from gas that had been shocked and compressed during the galactic merger, then collapsed in on itself. Witnessing one being born is unprecedented. 'The gas spans the entire width of the system and was likely shocked and compressed at the collision site,' they and their colleagues said in a study soon to be published in the Astrophysical Journal Letters. 'We suggest that the SMBH formed within this gas in the immediate aftermath of the collision, when it was dense and highly turbulent.' There are two main hypotheses for how supermassive black holes form. The 'light seeds' theory claims that supermassive black holes are the product of black holes that form after massive stars go supernova, collapsing in on themselves in violent explosions. These black holes then merge into larger black holes. The problem is that it would not only take an extremely long time for a supermassive black hole to form this way, this theory also cannot explain the existence of supermassive black holes, already observed by Webb, which were around when the universe was still young. The 'heavy seeds' hypothesis suggests that immense clouds of gas that collapse usually form stars, but sometimes, the gases collapse directly into supermassive black holes. This is the theory that seems to align with the more recent observations. About a few hundred million years after the universe dawned, clouds of gas in the middle of what would become galaxies collapsed. Hiding in those gaseous clouds were the seeds of supermassive black holes, whose powerful outflows and magnetic storms caused surrounding gas to collapse into multitudes of new stars. This explains the high populations of stars around galactic nuclei. 'If our proposed scenario is confirmed, the Infinity galaxy provides an empirical demonstration that direct-collapse formation of SMBHs can happen in the right circumstances—something that has so far only been seen in simulations and through indirect observations,' Brammer and van Dokkum said. More observations with Webb and other telescopes could finally reveal what a supermassive black hole's baby pictures look like. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life? Solve the daily Crossword

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

Fast Company

timean hour ago

  • Fast Company

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

Health-related stocks are not having a good day. First, America's largest health insurance provider, UnitedHealth Group (NYSE: UNH), saw its stock drop more than 4% this morning after the company announced disappointing second-quarter results and a full-year 2025 forecast that concerned investors. And now, the Danish pharmaceutical giant Novo Nordisk A/S, whose shares (NYSE: NVO) trade on the New York Stock Exchange, is seeing its stock price plunge, too. Currently, NVO shares are down more than 20% at the time of this writing. But unlike UnitedHealth Group, Novo Nordisk has not reported its most recent quarterly results. So what's sending its shares lower? Here's what you need to know. Novo Nordisk cuts full-year 2025 guidance The main driver of Novo Nordisk's significant share price fall today is the company's announcement that it is revising its previously published sales growth and operating profit growth for its full fiscal year 2025. On May 7, Novo Nordisk stated that it expected full-year fiscal 2025 sales growth to be between 13% and 21%. At the same time, it said it expected its operating profit growth to be between 16% and 24%. Now, however, the company had drastically cut both forecasts. Novo Nordisk now says it expects full-year fiscal 2025 sales growth to be between 8% and 14% and operating profit growth to be between 10% and 16%. In a statement, the company said its 'lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025.' This lowered growth is due to lower growth expectations for its GLP-1 weight loss and diabetes drugs, Wegovy and Ozempic, in the U.S. market. 'For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition,' the company said. It added that as far as Ozempic was concerned, 'the updated outlook is negatively impacted by competition in the U.S.' Novo Nordisk's main competitor in the GLP-1 arena is the American pharmaceutical giant Eli Lilly, who makes the drugs Mounjaro and Zepbound. Novo Nordisk names new CEO Besides revising its 2025 growth forecasts downward, Novo Nordisk also made another announcement today: It named a new CEO. However, this announcement probably had little to do with the stock's fall this morning. Back in May, Novo Nordisk announced that its longtime CEO Lars Fruergaard Jørgensen would be stepping aside. At the time, the company cited its declining share price as one of the reasons for the CEO shakeup. It also said Jørgensen would stay on as CEO until a successor was found. Now, one has been. Today, Novo Nordisk announced that Maziar Mike Doustdar will be assuming the position of president and chief executive officer, effective August 7, 2025. Doustdar is currently the company's executive vice president of international operations. Announcing Doustdar's ascent to the CEO role, Novo Nordisk chair Helge Lund said: 'This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Doustdar will officially take over as CEO one day after the company reports its second quarter 2025 results on August 6. Novo Nordisk shares have fallen dramatically since last summer While the GLP-1 drugs Wegovy and Ozempic have been a massive source of growth and profits at Novo Nordisk in the first half of this decade, recently, the company has faced increased competition in the GLP-1 marketplace, which has partly contributed to investor concerns. Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down more than 57%. And since the beginning of 2025, the company's share price has declined more than 35%.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store